About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 4

Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents

NCT00534638•GlaxoSmithKline

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Infections, Papillomavirus

Interventions

Cervarix

Engerix-B

Locations

6

Finland

Locations (6)

GSK Investigational Site

Kotka, Finland

GSK Investigational Site

Kuopio, Finland

GSK Investigational Site

Lahti, Finland

GSK Investigational Site

Rauma, Finland

GSK Investigational Site

Tampere, Finland

GSK Investigational Site

Turku, Finland

Key Dates

Start Date

October 4, 2007

Primary Completion Date

December 17, 2014

Completion Date

December 17, 2014

Last Updated

November 15, 2019

Related Studies

COMPLETEDPhase 3

Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old

NCT01627561

Infections, Papillomavirus

COMPLETEDPhase 3

Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)

NCT00637195

Infections, PapillomavirusPapillomavirus Vaccines

COMPLETEDPhase 3

Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18

NCT00196937

Infections, Papillomavirus

COMPLETEDPhase 3

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

NCT01462357

Infections, Papillomavirus

COMPLETEDPhase 3

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176

Infections, Papillomavirus

COMPLETEDPhase 3

Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

NCT01190189

Infections, Papillomavirus

View all related studies

Sponsors

Lead Sponsor

GlaxoSmithKline

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 15, 2019Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions